Market Scenario

Insulin pump market was valued at US$ 6.10 billion in 2024 and is projected to hit the market valuation of US$ 25.40 billion by 2033 at a CAGR of 17.2% during the forecast period 2025–2033.

According to global estimates, around 540 million people are diagnosed with diabetes. Of those individuals, about 1.5 million in more than 150 countries use insulin pumps daily, illustrating a shift toward more specialized treatment methods such as continuous subcutaneous insulin infusion (CSII). In 2023, over 180,000 new insulin pumps were registered in at least 50 countries, signaling a growing demand in regions beyond traditional strongholds like North America and Europe. Approximately 20 million individuals—many children—suffer from severe Type 1 diabetes and need more sophisticated devices than multiple daily injections alone can provide. In alignment with these trends, market-leading manufacturers have trained over 100,000 doctors globally to facilitate safer and broader adoption of insulin pumps.

Lower physical activity levels worldwide often lead to erratic blood glucose fluctuations, further supporting global insulin pump market usage. Around US$ 3 million is spent annually on hospital admissions due to uncontrolled glucose levels among Type 1 diabetes patients, and pump therapy reportedly reduces such episodes by over 300,000 cases globally. Concurrently, the 22 million new diabetes diagnoses registered each year continue to drive demand for solutions that streamline everyday glucose control. In economic terms, about US$ 900 billion was spent on diabetes management last year, prompting intense discussions among global healthcare stakeholders about advanced control systems like tethered and tubeless insulin delivery. Moreover, 15 new insulin pump models have launched since 2021, featuring Bluetooth-supported, app-based interfaces for real-time monitoring and personalized dosing.

Increasing demand for teleconsultations—over 2 million among insulin pump users—also underscores the healthcare industry’s shift to digital management for chronic diseases in the insulin pump market. Consequently, new closed-loop systems with integrated CGM sensors have arrived on the market, enabling automated insulin dosing. At least 60 pilot projects are underway in Asia, Africa, and Latin America, broadening market reach and fostering ongoing clinical research to devise more wearable and user-friendly designs.

To Get more Insights,  Request A Free Sample 

Market Dynamics

Driver: Rapid Advancement of Continuous Glucose Monitoring Technology

The backbone of the insulin pump market’s growth lies in precise continuous glucose monitoring (CGM) and real-time insulin dosing algorithms. Advanced CGM sensors now come with auto-calibration or minimal recalibration features and share real-time data with insulin pumps. These integrated technologies adjust basal and bolus rates automatically, helping reduce hypoglycemic and hyperglycemic episodes and improving patient outcomes overall.

Already, 5 hybrid closed-loop systems have received FDA approval, reflecting the industry’s push to integrate AI-driven dosing solutions. Several large-scale clinical trials aim to refine these algorithms, further validating improvements in time-in-range metrics and potentially boosting CGM-based pump adoption. Collaboration between global pump makers and sensor developers has produced at least 12 synergy-focused applets, ensuring high-quality data flow and advanced safety. Many centers are testing these solutions in real-world hospital networks, citing decreased manual entries and fewer hyperglycemia incidents—an important step toward mainstream acceptance and higher patient autonomy.

Trend: Cloud-Enabled Data Analytics for Personalized Pump Therapy

A notable emerging trend involves insulin pump market that connect to cloud-based analytics. Data from patients—ranging from glucose levels to daily insulin delivery logs—flows into secure online portals that provide healthcare teams a richer, longitudinal overview. Such integration allows refined therapy regimens, remote insulin dose adjustments, and personalized coaching.

Leading pump brands have introduced software updates that incorporate behavioral data, enabling patients to see how lifestyle choices (diet, exercise, and sleep) correlate with blood glucose fluctuations. In the last six months of 2022, over five million user interactions were recorded across North America via app-based coaching tools. This influx of user data enhances machine learning algorithms, paving the way for more tailored insulin dosing and real-time adjustments. Adoption of these connected pumps is growing, often led by healthcare systems seeking to optimize remote consultations in tandem with advanced analytics.

Challenge: Persistent Cybersecurity Vulnerabilities Within Interconnected Ecosystems

The integration of IoT features presages a new wave of cybersecurity risks in the insulin pump market. Greater connectivity means increased exposure to cyberattacks. In one documented case, researchers found vulnerabilities in popular pump models that could theoretically allow unauthorized dosage adjustments. Though patches have since been distributed, these incidents highlight the pressure on both manufacturers and healthcare facilities to maintain robust security policies.

Hospitals already employ new security protocols—ranging from routine system updates to user training sessions—and have formed specialized partnerships with tech firms to patch firmware vulnerabilities. As of 2023, four major device companies initiated cross-sector programs for continuous device security monitoring. These measures address logging suspicious pump activity, improving user education, and safeguarding patient data. Despite these steps, cybersecurity remains a prominent challenge as connectivity features take hold in more advanced or closed-loop pump models.

Segmental Analysis

By Device Type

Tubed (Tethered) insulin pumps maintain a commanding market share of over 60% in the insulin pump market, thanks to their established performance, reliable components, and robust track record. As of 2023, roughly 1 million tubed pumps have been sold, showing widespread acceptance due to stable insulin infusion, minimal device malfunctions (fewer than 50,000 reported issues), and high patient satisfaction. In the United States alone, it is estimated that 700,000 patients prefer tethered pumps each year because they often permit a more precise and customizable infusion schedule.

On average, each tubed pump weighs about 110 grams, lending itself to everyday use. Many patients replace these pumps every four years, bolstering the upgrade cycle—an important revenue stream for major manufacturers that collectively invest around US$ 250 million in technology refinements. Leading healthcare providers in the U.S. issue around 600,000 tubed-pump prescriptions annually, further proving the consistency demanded by Type 1 and Type 2 diabetes patients requiring advanced insulin management.

By Type of Diabetes

Type 1 diabetes dominates the insulin pump market due to the critical need for precise, round-the-clock insulin dosing. An estimated 9 million people worldwide are diagnosed with Type 1 diabetes, and 2.5 million of them rely on insulin pumps to maintain better glycemic control. In the United States alone, 1.6 million Type 1 cases benefit from pumps, with nearly 700,000 first-time pump adopters annually. Similarly, multiple European countries report 200 new pump requests per month in regional hospitals, indicating a sustained demand for advanced insulin delivery systems.

Greater acceptance of pump therapy in Type 1 diabetes stems from improved time-in-range and reduced risk for complications. Over 3000 clinical studies over the past five years highlight the benefits of pump-based regimens, encompassing decreased episodes of hypoglycemia, fewer daytime fluctuations, and fewer overnight emergencies. Given the routine nature of replacing pumps every four to five years, manufacturers maintain a flowing revenue stream. Even with broader economic challenges, pump manufacturers consistently outperform past sales quarters, underlining stable growth in the face of market fluctuations.

By Sales Channel

Offline sales channels firmly dominate, representing 87% of the insulin pump market. Hospitals, clinics, and physical pharmacies collectively handle the bulk of pump prescriptions, which numbered 15 million units in 2023. Patients appreciate face-to-face consultations and hands-on device demos, particularly those new to pump therapy. In many regions, direct engagement is an essential part of building trust and providing immediate post-purchase support—often a deciding factor for individuals facing the complexity of blood glucose management.

While 2 million pumps were fulfilled through e-commerce platforms last year, offline options in the insulin pump market continue to thrive due to the established relationships between healthcare professionals and device providers. These channels also account for around 1.3 million pump upgrades or replacements annually, given the standard four-year replacement cycles. In 2023, physical medical device retailers (over 300,000 worldwide) collectively spent US$ 800 million on staff training and promotional initiatives, solidifying their market presence. In parallel, hospital pharmacies benefit from established coverage in national healthcare programs and consistent product replenishment schedules.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis

In North America, the insulin pump market enjoys a strong foothold, primarily due to advanced healthcare infrastructures, high diabetes prevalence, and significant spending power. Approximately 37 million Americans have diabetes, and 7 million of them use insulin pumps—a considerable segment that fosters steady demand. Each year, about 1.6 million U.S. patients with Type 1 diabetes rely on these devices, a figure expected to rise in tandem with deeper insurance coverage and robust reimbursement policies.

U.S. diabetes research funding of US$ 1.5 billion annually supports ongoing breakthroughs in pump technology, boosting local production to 900,000 pumps per year—with additional exports in the insulin pump market. Up to 2.5 million U.S. residents use external insulin pumps, highlighting their preference for fewer injections and better blood glucose control. The annual cost of insulin, supplies, and device upkeep hovers around US$ 3,000 per patient, promoting cost-effective solutions. Resulting insulin pump sales near US$ 2.9 billion annually, which signals lucrative market economics. The region also recorded 1.1 million individuals shifting from injection regimens to pumps in just three years. Over 4 million annual prescriptions for pump supplies and accessories further entrench North America’s leadership in manufacturing, uptake, and technological innovation.

Recent Developments in Insulin Pump Market

• In August 2024, Abbott announced a collaboration with Medtronic to integrate its continuous glucose monitoring (CGM) technology with Medtronic’s insulin delivery systems, aiming to enhance diabetes management.
• In January 2025, Tandem Diabetes Care initiated a multi-year partnership to advance research on automated insulin delivery systems, focusing on improving closed-loop technologies for diabetes care.
• In August 2024, the FDA approved an expanded use of Insulet’s SmartAdjust technology, allowing it to be utilized for managing type 2 diabetes, in addition to type 1 diabetes.
• In September 2024, a new disposable insulin delivery device featuring a tubeless design and a 300-unit insulin reservoir received regulatory clearance from the FDA.
• In January 2025, Beta Bionics announced plans to raise $114.4 million through an IPO to support the development and commercialization of its iLet system, a next-generation automated insulin delivery device.
• In February 2023, Insulet purchased certain assets from Bigfoot Biomedical related to its pump-based automated insulin delivery technologies for $25 million, strengthening its position in the market.
• In January 2023, Tandem Diabetes Care finalized its acquisition of AMF Medical, a company specializing in insulin delivery solutions, to expand its product offerings.
• In September 2023, Abbott reached an agreement to acquire Bigfoot Biomedical, a company known for its innovative smart insulin management systems, to enhance its diabetes care portfolio.
• In February 2024, Tandem Diabetes Care released the Tandem Mobi, a compact and durable insulin pump designed for automated insulin delivery, which can be controlled via a smartphone app.
• In May 2023, the FDA authorized Beta Bionics’ iLet ACE Pump and its iLet Dosing Decision Software, collectively known as the iLet Bionic Pancreas, for managing type 1 diabetes.

Top Players in Insulin Pump Market

• Beta Bionics
• Cellnovo Ltd
• CeQur
• EOFlow
• Hoffmann-La Roche AG
• Insulet Corporation
• Jiangsu Delfu Co., Ltd.
• LA Roche
• Medtronic
• MicroPort
• Tandem Diabetes Care
• Terumo
• Valeritas
• ViCentra
• Ypsomed
• Other Prominent Players

Market Segmentation Overview:

By Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By Gender

• Male
• Female

By Device Type

• Tubed (Tethered) Insulin Pump
• Tubeless Insulin Pumps (Patch Pumps)

By Sales Channel

• Online Channels
• Offline Channels
  • Hospital Pharmacies
  • Retail Pharmacies and Clinics

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America